A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03586973

Recruitment Status : Completed

First Posted : July 16, 2018

Last Update Posted : August 27, 2021

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Takeda

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	July 17, 2019
Actual Study Completion Date :	June 29, 2021

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	June 14, 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kudo M, Tsuchiya K, Kato N, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Furuse J, Ikeda M, Morimoto M, Achira M, Kuroda S, Kimura A. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. J Gastroenterol. 2021 Feb;56(2):181-190. doi: 10.1007/s00535-020-01753-0. Epub 2021 Jan 3.

To Top